AstraZeneca : Phase III Trial Data Show Danicopan Sustained Clinical Improvements In PNH

(RTTNews) - AstraZeneca (AZN, AZN.L) said that positive results from the 24-week and long-term extension period of the pivotal ALPHA Phase III trial showed danicopan as add-on to standard of care C5 inhibitor therapy Ultomiris (ravulizumab-cwvz) or Soliris (eculizumab) continued https://www.nasdaq.com/articles/astrazeneca-:-phase-iii-trial-data-show-danicopan-sustained-clinical-improvements-in-pnh